
|Articles|March 1, 2003
Multifaceted Topical
Pittsburgh -Topical tacrolimus ointment 0.1 percent (Protopic) may be a viable addition to the current therapeutic armamentarium for early-stage cutaneous T-cell lymphoma (CTCL), Larisa Geskin, M.D., said.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
2
Transformative Advances This Year and Beyond
3
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
4
KT-621 Produces 98% STAT6 Degradation in AD Patients
5



















